219 related articles for article (PubMed ID: 24754603)
1. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.
Shihab FS; Olyaei A; Wiland A; McCague K; Norman DJ
Clin Transplant; 2014 Jul; 28(7):768-75. PubMed ID: 24754603
[TBL] [Abstract][Full Text] [Related]
2. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
[TBL] [Abstract][Full Text] [Related]
6. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study.
Narayanan M; Pankewycz O; Shihab F; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Feb; 28(2):184-91. PubMed ID: 24372743
[TBL] [Abstract][Full Text] [Related]
9. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry.
Ueda K; McCague KM; Wiland A; Peddi VR
Ann Transplant; 2014 Feb; 19():84-92. PubMed ID: 24535029
[TBL] [Abstract][Full Text] [Related]
10. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
[TBL] [Abstract][Full Text] [Related]
11. Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry.
Doria C; Greenstein S; Narayanan M; Ueda K; Wiland A; McCague K; Sankari B; Chan L
Clin Transplant; 2012; 26(6):E602-11. PubMed ID: 23121178
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone.
Beermann KJ; Ellis MJ; Sudan DL; Harris MT
Clin Transplant; 2014 Jul; 28(7):762-7. PubMed ID: 24754564
[TBL] [Abstract][Full Text] [Related]
14. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study.
Trunečka P; Klempnauer J; Bechstein WO; Pirenne J; Bennet W; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Kazeem G; Tisone G
Ann Transplant; 2019 Jun; 24():319-327. PubMed ID: 31160549
[TBL] [Abstract][Full Text] [Related]
16. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
17. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.
Hoitsma AJ; Woodle ES; Abramowicz D; Proot P; Vanrenterghem Y;
Nephrol Dial Transplant; 2011 Nov; 26(11):3802-5. PubMed ID: 21911597
[TBL] [Abstract][Full Text] [Related]
18. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.
Langone A; Doria C; Greenstein S; Narayanan M; Ueda K; Sankari B; Pankewycz O; Shihab F; Chan L
Clin Transplant; 2013; 27(1):15-24. PubMed ID: 22861144
[TBL] [Abstract][Full Text] [Related]
19. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
Tönshoff B; Ettenger R; Dello Strologo L; Marks SD; Pape L; Tedesco-Silva H; Bjerre A; Christian M; Meier M; Martzloff ED; Rauer B; Ng J; Lopez P
Am J Transplant; 2019 Mar; 19(3):811-822. PubMed ID: 30125462
[TBL] [Abstract][Full Text] [Related]
20. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]